Korean J Nephrol.  2005 May;24(3):448-454.

The Cutcome of Living-related Renal Transplantation with Previously Positive but Currently Negative HLA Crossmatching

Affiliations
  • 1Department of Internal Medicine, The Institute of Renal Disease, College of Medicine, Ulsan University, Seoul, Korea. sk-park@amc.seoul.kr
  • 2Department of Laboratory Medicine, College of Medicine, Ulsan University, Seoul, Korea.

Abstract

PURPOSE
Previously positive but currently negative HLA crossmatching is considered to be a risk factor not in the first renal transplantation but in the second renal transplantation. The aim of this study is to analyse the outcome of living-related renal transplantation with previously positive but currently negative HLA crossmatching. METHODS: The results of first HLA crossmatching, demographic characteristics, the outcome of renal trasplantation were examined in four patients undergoing renal transplantation with previously positive but currently negative HLA crossmatching. RESULTS: The acute rejection was occurred in 3 patients. Azotemia was improved with the immunosuppressive therapy containing tacrolimus. There were no graft failures in four patients for 1 year. In the first HLA crossmatching, anti-human globulin T cell HLA crossmatching was positive in all patients with acute rejection. The period that positive HLA crossmatchings were converted to negative was longer in patients with acute rejections than without acute rejections (177 days vs 22 days). CONCLUSION: There were 3 acute rejections in 6 patients undergoing living related renal transplantations with previously positive and current negative HLA crossmatching. There were no graft failure for 1 year.

Keyword

HLA crossmatching; Renal trasplantation

MeSH Terms

Azotemia
Humans
Kidney Transplantation*
Risk Factors
Tacrolimus
Transplants
Tacrolimus
Full Text Links
  • KJN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr